Skip to main content
ANVS
NYSE Life Sciences

Annovis Bio Reports Strong Phase 3 AD Trial Progress, Positive Safety Data, and Updated Cash Position

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$2.06
Mkt Cap
$71.137M
52W Low
$1.541
52W High
$5.5
52W Position info
34% above low
Off High info
63% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ANVS sits 34% above its 52-week low of $1.541.

Summary

Annovis Bio announced significant progress in its Phase 3 Alzheimer's trial and an improved cash position following a recent offering, providing a lifeline despite increased losses.


Key Events · Product Development and Regulatory · ANVS

  • Pivotal Phase 3 AD Trial Progress

    85% patient enrollment achieved in the Alzheimer's disease trial, with full enrollment expected by summer 2026. The Data and Safety Monitoring Board (DSMB) issued a positive safety recommendation at 6 months.

  • NDA Pathway Defined

    The company anticipates engaging with the FDA for a New Drug Application (NDA) submission for buntanetap as a symptomatic treatment for Alzheimer's in early 2027, and as a disease-modifying treatment in early 2028.

  • Updated Cash Position

    Cash and cash equivalents totaled $14.2 million as of March 31, 2026. This figure excludes the gross proceeds from a $10 million underwritten offering completed on April 10, 2026, which significantly bolstered the company's liquidity.

  • Increased Net Loss

    The company reported a net loss of $17.6 million for Q1 2026, nearly doubling from $5.5 million in Q1 2025, primarily driven by a substantial increase in research and development expenses to $16.7 million.


Analysis · ANVS · Life Sciences

Annovis Bio provided critical updates on its pivotal Phase 3 Alzheimer's trial, including 85% patient enrollment and a positive 6-month safety recommendation from the Data and Safety Monitoring Board. The company also outlined clear New Drug Application (NDA) timelines for buntanetap. While the first-quarter net loss nearly doubled due to increased R&D, the reported cash balance of $14.2 million as of March 31, 2026, combined with the subsequent $10 million offering in April, provides a temporary extension to its financial runway, which is crucial given previous "going concern" warnings.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANVS was trading at $2.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $71.1M. The 52-week trading range was $1.54 to $5.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 13, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.780 info
Change: -$0.160 (-17%) info
Market Cap: $32.009M info
ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.780 info
Change: -$0.0999 (-11%) info
Market Cap: $32.009M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.780 info
Change: -$0.0889 (-10%) info
Market Cap: $32.009M info
ANVS
Nov 04, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.780 info
Change: -$0.160 (-17%) info
Market Cap: $32.009M info
ANVS
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8507
Real-time Price: $0.780 info
Change: -$0.0707 (-8%) info
Market Cap: $32.009M info